FDA assigns priority review to biologics license application for tezepelumab as treatment of patients with severe, uncontrolled asthma

Submission for this inhibitor of thymic stromal lymphopoietin is based on data from phase III NAVIGATOR trial in which tezepelumab added to standard of care (SoC) resulted in statistically significant reduction in annualised asthma exacerbation rate over 52 weeks vs placebo + SoC

Source:

PharmaTimes